Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Assess the Effectiveness of Esomeprazole 40 mg Once Daily in Subjects With Continuing Gastroesophageal Reflux Disease (GORD) Symptoms Following Treatment Wit a Previous Full Dose Proton Pump Inhibitor (PPI)

NCT00384592 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00384592
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00384592 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Assess the Effectiveness of Esomeprazole 40 mg Once Daily in Subjects With Continuing Gastroesophageal Reflux Disease (GORD) Symptoms Following Treatment Wit a Previous Full Dose Proton Pump Inhibitor (PPI)
Lead sponsor
AstraZeneca
Phase
Phase 4
Overall status
Completed
Start date
September 30, 2006
Completion date
May 31, 2007
Enrollment
100
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

gastro-oesophageal reflux disease